Helping patients make informed choices about probiotics: A need for research

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 809-813

  Sharp, Richard R ^a   Achkar, Jean Paul ^a   Brinich, Margaret A ^a   Farrell, Ruth M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ALTERNATIVE MEDICINE; ATTITUDE; DECISION MAKING; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; GASTROINTESTINAL DISEASE; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HEALTH HAZARD; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPROMISED PATIENT; MEDICAL RESEARCH; PATIENT INFORMATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TRADITIONAL MEDICINE; DOCTOR PATIENT RELATION; GASTROINTESTINAL DISEASES; INFORMED CONSENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PROCEDURES;

BIOMEDICAL RESEARCH; GASTROINTESTINAL DISEASES; HUMANS; INFORMED CONSENT; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PROBIOTICS;

EID: 65449161000     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.68     Document Type: Review

References (49)

1. Guarner F, Malagelada JR. Gut flora to health and disease. Lancet 2003;361:512-9.
2. Quigley EM, Quera R. Small intestinal bactertal overgrowth: roles of antibtotics, prebtottcs, and probtotics. Gastroenterology 2006;1 30(2 Suppl 1)S78-90.
3. Food and Agriculture Organization of the United Nations, and World Heahh Organizatton. Report on Joint FAQ/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Eactic Acid Bacteria. (2001). Accessed 7 February 2008.
4. Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulurdii in the prexention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;22:365-72.
5. Pillai A, Nelson R. Probiutics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rex [online] 23 January 200S;CD004611 (doi:tO.1002/14651858.CD004611.pub2).
6. Santosa 5, Farnworth E, Jones PJ. Probiutics and their potential health claims. Nutr Rev 2006;64:265-74.
7. Zuccotti GV, Meneghin F, Raimondi C et al. Probiotics in clinical practice: an overxiew. J Int Med Res 2008;36(Suppl 1):1A-53A.
8. Boyle R, Robins-Browne RM, Tang MEK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256-64.
9. Junkers 0, Stockbrügger R. Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007;26(Suppl 2):133-48.
10. Sartor RB. Probiutic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 2005;21:44-50.
11. Fedorak R, Madsen KE. Probiutics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004;20:146-55.
12. Fedorak R, Penner R, Madsen KE. Probiotics in the treatment of gastrointestinal disorders. US Gastruenterul Rev 2006;1:1-7.
13. O'Hara A, Shanahan 17 Mechanism of action of probiotics in intestinal disease. Sci Wodd J 2007;7:31-46.
14. Saier MH Jr, Mansour NM. Prubiutics and prebiotics in human health. Mol Microbial Biotechnol 2005;10:22-5.
15. Meier R, Steuerwald M. Place of prubiotics. Curr Opin Crit Care 2005;11:318-25.
16. Quattropani C, Ausfeld B, Straumann A et al. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 2003;38:277-82.
17. Besselink MG, van Santvuort HC, Buskens E et al. Probiutic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo- controlled trial. Eancet 2008;371:651-9.
18. Singhi S. Probiotics in the critically ill: handle with care! Pediatr Crit Care Med 2007;8:499-501.
19. Honeycutt TC, El Khashab M, Wardrop RIvI 3rd. Probiotic administration and the incidence of nusocumial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007;8:452-8.
20. Lata J, Novotn) I, PrIbramska V et al. The effect of probiotics on gut flora, level of endutuxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenteral Hepatal 2007;19:111l-3.
21. Malaguarnera M, Greco F, Barone G et al. Bifidobacterium longum with fructo-oligasaccharide (FOS) treatment in minimal hepatic encephalapathy: a randomized, double-blind, placebo-controlled study. Oig Dis Sci 2007;52:3259-65.
22. Rolfe VE, Furtun PJ, Hawkey CJ et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev [online] 18 October 2006;C0004826 (doi:1O.1002/t465t858.CD004826.pub2).
23. Guslandi M, Mezzi G, Sorghi M et al. Succharursiyces boulardit in maintenance treatment of Crohns disease. Dig Dis Sci 2000;45:1462-4.
24. P1ein K, Hotz J. Therapeutic effects of Saccharamyces baulardu on mild residual symptoms in a stable phase of Cruhn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993;31:129-34.
25. Kruis W, Fric P, Pokratnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as wish standard mesalazine. Gut 2004;53:1617-23.
26. Cui HH, Chen CL, Wang JD et al. Effects of probiatic on intestinal mucosa of patients With ulcerative colitis. World J Gastroenterol 2004;10:1521-5.
27. Verdü EF, BercIk P, Bergonzelli GE et al. Lactubacillus paracasei normalizes muscle hypercantractility in a murine model of pastinfectix e gut d) sfunctiun. Gastroenterology 2004;t27:826-37.
28. O'Mahony E, McCarthy J, Kelly P et al. Lactubacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytukmne profiles. Gastroenterology 2005;128:541-51.
29. Bittner AC, Croffut RM, Stranahan MC. Prescript-assist probiutic-prebiutic treatment fur irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005;27:755-61.
30. Guyunnet D, Chassany 0, Ducrotte P et al. Effect of a fermented milk containing Bifidohacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacal Ther 2007;26:475-86.
31. Gionchetti P. Eammers KM, Rizzello F et al. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenteral Clin N Am 2005;34:499-513.
32. Frank ON, St Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial communit) imbalances in human inflammatory bowel diseases. Proc Natl Acad Scm USA 2007;104:13780-5.
33. Frank ON, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterul 2008;24:4-lO.
34. Jia W, Li H, Zhao L et al. Gut micrubiota: a potential new territory fur drug targeting. Nat Rev Drug Discov 2008;7:123-9.
35. Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl 2):S104-11; discussion S144-51.
36. Eisenberg OM, Kessler RC, Van Rompay MIl et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001;135:344-51.
37. Karetz RL, Ratblatt M. Complementary and alternative medicine in gastroenterolugy: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004;2:957-67.
38. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-95.
39. Hu Z, Yang X, Ho PC et al. Herb-drug interactions: a literature review. Drugs 2005;65:1239-82.
40. Eisenberg OM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997;127:61-9.
41. Pappas 5, Perlman A. Complementary and ahernative medicine. The importance of doctor-patient communication. Med Clin North Am 2002;86:1-lO.
42. Paton AW, Morona R, Patun JC. Designer prubiotics fur prevention of enteric infections. Nat Rev Microbiol 2006;4:193-200.
43. Palling J. Strategies for helping patients understand risks. BMJ 2003;327:745-8.
44. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002;324:827-30.
45. Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med 2005;5:465-9.
46. Wade N. Patient dies during a trial of gene therapy. New York Times 29 September 1999:A24.
47. Walker R, Buckley M. Probiutic microbes: the scientific basis. American Academy of Microbiology, Washington, DC, 2006.
48. Steidler L. Genetically engineered prabiaticc. Best Pract Res Clin Gastraenterol 2003;17:861-76.
49. Messner M, Shaw 5, Regli S et al. An approach for developing a national estimate of waterborne disease due to drinking water and a national estimate model application.J Water Health 2006;4(Suppl 2):201-40.